Nutex Health Reports Robust 2025 Financials, 82.4% Revenue Growth, and Authorizes New $25M Share Repurchase
NUTX sits 75% above its 52-week low of $40.67 on elevated volume (2.2× avg).
Summary
Nutex Health Inc. reported robust 2025 financial results with significant revenue and Adjusted EBITDA growth, successfully remediated material weaknesses in internal controls, and authorized a new $25 million share repurchase program.
Key Events · Earnings and Guidance · NUTX
-
Strong 2025 Financial Performance Confirmed
Nutex Health Inc. reported total revenue of $875.3 million for 2025, an 82.4% increase from $479.9 million in 2024. Net income attributable to Nutex Health Inc. rose to $70.8 million ($10.48 diluted EPS) in 2025 from $52.1 million ($9.69 diluted EPS) in 2024. Adjusted EBITDA increased by 152.5% to $259.6 million in 2025 from $102.8 million in 2024.
-
Material Weaknesses in Internal Controls Remedied
The company announced the remediation of material weaknesses in its internal control over financial reporting as of December 31, 2025, which were previously disclosed for the year ended December 31, 2024. This is a significant positive for corporate governance and financial reporting reliability.
-
New $25 Million Share Repurchase Program Authorized
Following the completion of a prior $25 million share repurchase program in January 2026, the Board authorized a second stock repurchase program of up to $25.0 million on March 4, 2026. This indicates management's confidence in the company's value and commitment to returning capital to shareholders.
-
Significant Cash Position and Operating Cash Flow Growth
Cash and cash equivalents increased substantially to $185.6 million at December 31, 2025, from $40.6 million at December 31, 2024. Net cash provided by operating activities grew to $248.1 million in 2025 from $23.2 million in 2024.
Analysis · NUTX · Trade & Services
Nutex Health Inc. has filed its annual report, confirming strong financial performance for fiscal year 2025, including significant revenue and Adjusted EBITDA growth. This report also highlights the successful remediation of previously identified material weaknesses in internal control over financial reporting, a crucial step for corporate governance and investor confidence. Furthermore, the company has authorized a new $25 million share repurchase program, signaling management's belief in the company's valuation and commitment to shareholder returns. While the report details ongoing litigation and potential future share dilution from earn-out agreements, the overall picture is one of strong operational execution and improved financial health.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 35.6% of the 1216 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NUTX was trading at $71.31 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $745M. The 52-week trading range was $40.67 to $193.07. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.